Related Experiment Video

Updated: May 24, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Adjuvant chemotherapy for soft tissue sarcomas

Vinod Ravi1, Shreyaskumar Patel

  • 1Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. vravi@mdanderson.org

Surgical Oncology Clinics of North America
|February 28, 2012
PubMed

Insights

Soft tissue sarcomas are rare cancers. For high-risk patients, neoadjuvant or adjuvant therapy can improve outcomes by reducing recurrences, especially with histology-specific trials.

Area of Science:

  • Oncology
  • Surgical Pathology
  • Medical Oncology

Background:

  • Soft tissue sarcomas are rare, heterogeneous mesenchymal neoplasms.
  • Most patients present with localized disease, curable with multidisciplinary treatment.
  • High-risk patients benefit from neoadjuvant/adjuvant therapy to prevent metastasis.

Purpose of the Study:

  • To review the role of neoadjuvant/adjuvant therapy in soft tissue sarcomas.
  • To highlight the importance of histology-specific trials for high-risk populations.
  • To recommend neoadjuvant chemotherapy for specific chemosensitive subtypes.

Main Methods:

  • Review of current literature on soft tissue sarcoma treatment.
  • Analysis of outcomes from histology-specific versus heterogeneous patient trials.
  • Evaluation of neoadjuvant/adjuvant therapy efficacy in high-risk patients.

Main Results:

  • Neoadjuvant/adjuvant therapy can decrease local and distant recurrences in high-risk patients.
  • Histology-specific trials yield more reliable benefit data than broad trials.
  • Chemosensitive subtypes show improved outcomes with neoadjuvant chemotherapy.

Conclusions:

  • Multidisciplinary treatment is key for localized soft tissue sarcomas.
  • Neoadjuvant/adjuvant strategies are crucial for high-risk patients to prevent metastasis.
  • Tailoring therapy based on histology and response is recommended for optimal outcomes.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...